For an optimal site experience, we recommend using a different browser.
Using Internet Explorer may prevent you from accessing Chubb.com, and some site features may not function as expected.

X
skip to main content

The urgency of the COVID-19 health crisis has led to a frenzy of clinical trial activity. After the Chinese authorities shared the COVID-19 genome with the international community in January 2020, it took just six weeks for the first candidate vaccine to be shipped for human clinical trials. By early August 2020, close to 3,000 trials were under way around the world, attempting to halt the progress of COVID-19 at different points along the biochemical pathway it takes into the human body. The pace at which these candidates were prepared shows how far both our understanding of the disease has come and the speed with which science can move.

However, with all eyes on the goal of beating COVID-19 fast and the scientific and medical communities throwing everything they have at COVID-19, there are risk implications not only for the researchers running trials, but also for product owners whose drugs are being tested against the disease. While the regulatory environment is allowing for fast-tracked trials and greater leniency, this will not extend to compromised patient safety.

 

The context may be a very immediate health crisis, but the trade-offs being made are creating long-term risks that someone will be liable for and which must be managed accordingly.

 

Read the “Emerging Risks in COVID-19 Clinical Trials” report to learn more about the emerging risks and how they can be mitigated.

Key takeaways

  • It would be unwise for researchers to give drugs to research subjects who could otherwise be excluded.
  • Changes and revisions to primary endpoints should be uncommon.
  • Product manufacturers should stay alert to how their products are being used.
  • Regulations may have been relaxed but product liability law remains the same.
  • Lessons are being learnt about how to structure trials more efficiently and global coordination.

Emerging Risks in COVID-19 Clinical Trials

 

Read more reports in the ‘Life Science in the era of pandemics’ series:

Making Medical Devices During a Pandemic
Fighting COVID-19 with genomics
The Great Telehealth Experiment
Lessons from the Supply Chain


This content is brought to you by Chubb Insurance Malaysia Berhad, Registration No. 197001000564 (9827-A) (“Chubb”) as a convenience to readers and is not intended to constitute advice or recommendations upon which a reader may rely. Any references to insurance cover are general in nature only and may not suit your particular circumstances. Chubb does not take into account your personal objectives, financial situation or needs and any insurance cover referred to is subject to the terms, conditions and exclusions set out in the relevant policy wording. Please obtain and read carefully the relevant insurance policy before deciding to acquire any insurance product. A policy wording can be obtained at www.chubb.com/my, through your broker or by contacting any of the Chubb offices or Chubb agents. Chubb makes no warranty or guarantee about the accuracy, completeness, or adequacy of this content. It is the responsibility of the reader to evaluate the quality and accuracy of material herein.

© 2022 Chubb. Not all coverages available in all jurisdictions. Chubb® and its respective logos, and Chubb. Insured.℠  are protected trademarks of Chubb.

Tips and Resources

We help you stay ahead and informed with these helpful tips and tricks

Have a question or need more information?

Contact us to find out how we can help you get covered against potential risks